PROVECTUS BIOPHARMACEUTICALS, INC.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
PVCT$0.04-17.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| For the Three Months Ended · For the Six Months Ended | ||||||
|---|---|---|---|---|---|---|
| June 30, · June 30, | ||||||
| 2026 · 2025 · 2026 · 2025 | ||||||
| Grant Revenue | $ | - | $57,480 | $ | - | $336,108 |
| Operating Expenses: | ||||||
| Research and development | 131,130 | 880,835 | 464,464 | 1,282,987 | ||
| General and administrative | 807,548 | 977,373 | 1,722,117 | 1,951,790 | ||
| Total Operating Expenses | 938,678 | 1,858,208 | 2,186,581 | 3,234,777 | ||
| Total Operating Loss | (938,678) | (1,800,728) | (2,186,581) | (2,898,669) | ||
| Other Income (Expense): | ||||||
| Research and development credit | 281 | - | 281 | - | ||
| Interest expense | (50,319) | (51,353) | (103,365) | (115,014) | ||
| Total Other Expense, Net | (50,038) | (51,353) | (103,084) | (115,014) | ||
| Net Loss | (988,716) | (1,852,081) | (2,289,665) | (3,013,683) | ||
| Net Loss attributable to noncontrolling interest | (6,150) | (37,661) | (16,645) | (59,155) | ||
| Net Loss attributable to common stockholders | $(982,566) | $(1,814,420) | $(2,273,020) | $(2,954,528) | ||
| Basic and Diluted Loss Per Common Share | $(0.00) | $(0.00) | $(0.01) | $(0.01) | ||
| Weighted Average Number of Common Shares Outstanding - Basic and Diluted | 420,279,879 | 420,279,879 | 420,279,879 | 420,279,879 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.